Irritable bowel syndrome (IBS) poses a significant global health challenge, impacting millions
Our focus is on providing a breakthrough solution for IBS-D patients through NORDBIOTIC™ IBS 10, a multi-strain probiotic preparation.
With a prevalence of 20% globally, IBS demands effective, safe interventions. NORDBIOTIC™ IBS 10 targets the multifactorial aspects of IBS, addressing symptoms such as pain severity and quality of life.
Irritable bowel syndrome (IBS) symptoms
- sharp, cramping pains in the abdomen
- relief from defecation or gas diarrhea (the diarrheal form of IBS)
- constipation – in patients without diarrhea
- abdominal distension, gases
- nausea, vomiting
- headaches
- fatigue
Dysbiosis in IBS
Reducing the number of Lactobacillus and Bifidobacterium
Increase the numer of Streptococcus and Clostridium
Change in the ratio between Firmicutes and Bacteroidetes (decrease in the number of Bacteroidetes)
In patients with IBS, the risk of SIBO (increase in the number of bacteria in the small intestine) is about 5 times higher than in the control group (OR = 4.7, 95 CI: 3.1-7.2)
Probiotics in IBS
Numerous randomized controlled studies confirm the effectiveness of probiotics in the treatment of IBS (currently about 40 randomized controlled studies)
Probiotics have a positive effect on the perception of pain, flatulence and improve the quality of life of patients
The effectiveness of probiotics has been confirmed in recently published meta-analyzes of randomized controlled trials
NORDBIOTIC™ IBS 10 STUDY
The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study
Dosage
Recommended Daily Dossage: 5 x 10⁹ CFU
Duration
8 weeks
Safety
Impeccably well-tolerated with no reported adverse events
Conclusion
NORDBIOTIC™ IBS 10 the multi-strain probiotic blend, taken at 5 billion CFU daily for 8 weeks, outperformed a placebo. Well-tolerated and safe, it notably improved global IBS symptoms and specific issues like pain severity and quality of life. These results highlight the concrete advantages of our multi-strain probiotic for IBS adults.
Key proven benefits
Significant reduction in IBS symptom severity (IBS-SSS).
Improved quality of life.
Superior pain relief.
Enhanced global symptom improvement (IBS-GIS) – 92% of patients in NORDBIOTIC™ IBS 10 group showed significant improvement.
Tested strains
- Lacticaseibacillus rhamnosus LR110 / 1,11 x 10⁹ cfu
- Bifidobacterium lactis BI 040 / 0,835 x 10⁹ cfu
- Bifidobacterium breve BB010 / 0,415 x 10⁹ cfu
- Lacticaseibacillus paracasei LPC100 / 0,415 x 10⁹ cfu
- Lactobacillus acidophilus LA120 / 0,415 x 10⁹ cfu
- Lacticaseibacillus casei LR130 / 0,415 x 10⁹ cfu
- Lactiplantibacillus plantarum LP140 / 0,415 x 10⁹ cfu
- Streptococcus thermophilus ST250 / 0,415 x 10⁹ cfu
- Bifidobacterium longum BL020 / 0,280 x 10⁹ cfu
- Bifidobacterium bifidum BF030 / 0,280 x 10⁹ cfu
92% of patients in NORDBIOTIC™ IBS 10 group show significant improvement
IBS-Global Improvement Scale (IBS-GIS)
60% of patients in NORDBIOTIC™ IBS 10 group have mild IBS and none severe IBS
IBS- Severity Scoring Scale (IBS-SSS)
52% of patients in NORDBIOTIC™ IBS 10 group show improvement
IBS- Severity Scoring Scale (IBS-SSS)
36% of patients in NORDBIOTIC™ IBS 10 group indicate pain relief
IBS- Severity Scoring Scale (IBS-SSS)
Why do clinically tested probiotics matter?
NORDBIOTIC™ IBS 10 |
Non-clinically tested probiotics |
|
|---|---|---|
Proven effectiveness |
 |
 |
Safety and reliability |
|
|
Strain specificity |
|
|
Trust and transparency |
|
|